Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-05-31

Study Completion Date

2007-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the effectiveness and safety of atomoxetine in the treatment of adolescents with coexisting alcohol or substance use disorders and Attention Deficit Hyperactivity Disorder (ADHD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder

NCT00142961

Attention Deficit Disorder With Hyperactivity Marijuana Abuse

COMPLETED PHASE2

Effectiveness of ATMX in Treating Adolescents With ADHD and SUD

NCT00218322

Attention Deficit Disorder With Hyperactivity Substance-Related Disorders

COMPLETED PHASE4

Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse

NCT00190957

ADHD Comorbid Alcohol Abuse

COMPLETED PHASE4

Enhancing the Effects of Adolescent Alcohol Treatment With Atomoxetine

NCT04565288

Alcohol Use Disorder

COMPLETED PHASE2

Efficacy of Atomoxetine for ADHD in Adolescents and Young Adults With SUD

NCT01207622

Attention Deficit Hyperactivity Disorder Substance Use Disorder

WITHDRAWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Substance Use Disorders Attention Deficit Hyperactivity Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Atomoxetine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adolescents, ages 13-18
* Meets criteria for alcohol and/or substance use disorder and attention deficit hyperactivity disorder.

Exclusion Criteria

* Adolescents who are pregnant.
* Have a history of seizure disorder, other neurological or medical disorder for which medication treatment may present a considerable risk.
* History of pervasive development disorder, schizophrenia or other psychotic disorders, organic mental disorders or eating disorders.
* Currently on other psychotropic medications from which discontinuation would present a significant risk.
* A current episode of major depressive disorder or a diagnosis of bipolar disorder.
* Diagnosis of dependence for any substance other than marijuana.
* Adolescents with a full-scale IQ below 80.

Minimum Eligible Age

13 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No